Comparing radiation therapy alone or with cisplatin for advanced head and neck cancer after surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase II trial investigates the effectiveness of radiation therapy, with or without the chemotherapy drug cisplatin, in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgical resection. Patients are randomized into two groups: one receiving only radiation therapy and the other receiving radiation therapy alongside cisplatin. The study aims to evaluate disease-free survival rates and the potential role of p53 mutations as predictive biomarkers for treatment outcomes. Additionally, the trial will assess the toxicities associated with each treatment approach.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* PRE-REGISTRATION (STEP 0)
* Pathologically proven diagnosis of squamous cell carcinoma (including variants such as verrucous carcinoma, spindle cell carcinoma, carcinoma not otherwise specified \[NOS\]) of the head/neck (oral cavity, oropharynx, hypopharynx or larynx); pathologic stage III or IVA (American Joint Committee on Cancer \[AJCC\] 8): T3-T4a, N0-3, M0 or T1-T2, N1-3, M0
* Patient has undergone total resection of the primary tumor with curative intent

  * NOTE: Patient is to be pre-registered to screening (Step 0) and tissue submitted to Foundation Medicine as soon as possible after surgery in order to meet the 8 week deadline to register the patient to Step 1 after surgery; full assay minimum turn-around time is 17-24 days
* For oropharynx primary tumors, the patient must have negative human papillomavirus (HPV) status of the tumor as determined by p16 protein expression using immunohistochemistry (IHC)
* Patients with, per the operative and/or pathology report, positive margin(s) (tumor present at the cut or inked edge of the tumor) which is not superceded by an additional margin of tumor-negative tissue, nodal extracapsular extension, and/or gross residual disease after surgery are not eligible
* A paraffin-embedded surgical tumor tissue specimen has been located is available for shipment to Foundation Medicine, Inc. following pre-registration

  * NOTE: Complete the EA3132-specific FoundationOne requisition form
* Patients with a history of a curatively treated malignancy must be disease-free for at least two years except for carcinoma in situ of cervix and/or non-melanomatous skin cancer; patients must not have received chemotherapy or investigational therapy within two years of surgical resection of the primary tumor
* Patient must not have had previous irradiation to the head and neck that would result in overlap in radiation fields for the current disease
* Patients with recurrent disease or multiple primaries are ineligible
* RANDOMIZATION (STEP 1)
* NOTE: Patient must meet all eligibility criteria outlined in pre-registration; patient may not be randomized until site has been notified that the central determination of p53 mutation status of the surgical tumor tissue has been completed and site has been notified of assay completion
* Per the operative report, the gross total resection of the primary tumor with curative intent was completed within 8 weeks prior to randomization
* The patient must have the following assessments done =\< 8 weeks prior to randomization:

  * Examination by a head and neck surgeon
  * Chest x-ray (or chest computed tomography \[CT\] scan or CT/positron emission tomography \[PET\] of the chest or magnetic resonance imaging \[MRI\]) to rule out distant metastatic disease
* Patient has Eastern Cooperative Oncology Group (ECOG) performance status 0-1 within 2 weeks prior to randomization
* Women must not be pregnant or breast-feeding; females of childbearing potential must have a blood or urine study within 2 weeks prior to randomization to rule out pregnancy; a female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
* Women of childbearing potential and sexually active males must be strongly advised to use an accepted and effective method of contraception or to abstain from sexual intercourse for the duration of their participation in the study and until 60 days from the last study treatment
* Absolute neutrophil count \>= 1,500/mm\^3 within 4 weeks prior to randomization
* Platelets \>= 100,000/mm\^3 within 4 weeks prior to randomization
* Total bilirubin =\< the upper limit of normal (ULN) within 4 weeks prior to randomization
* Calculated creatinine clearance must be \> 60 ml/min using the Cockcroft-Gault formula within 4 weeks prior to randomization
* Patient must not have an intercurrent illness likely to interfere with protocol therapy

Where it's running

• Anchorage Associates in Radiation Medicine
  Anchorage, Alaska, United States Recruiting
• Alaska Breast Care and Surgery LLC
  Anchorage, Alaska, United States Recruiting
• Alaska Oncology and Hematology LLC
  Anchorage, Alaska, United States Recruiting
• Alaska Women's Cancer Care
  Anchorage, Alaska, United States Recruiting
• Katmai Oncology Group
  Anchorage, Alaska, United States Recruiting
• Providence Alaska Medical Center
  Anchorage, Alaska, United States Recruiting

+629 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Principal investigator: Robert Ferris — ECOG-ACRIN Cancer Research Group

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Adding BMX-001, a drug that protects normal tissue from radiation damage, to standard chemoradiation for head and neck cancer

  This trial tests whether giving BMX-001 along with usual mouth-care reduces severe mouth sores in people getting cisplatin-based chemoradiation for HPV-related and other head and neck cancers.

  Recruiting at 146 sites Phase 2 NRG Oncology · Gilbert, Arizona and 152 other locations · NCT06532279

• Comparing two imaging techniques for assessing blood vessel effects in head and neck cancer patients receiving radiation therapy

  This study is testing if a new type of imaging can better spot blood vessel problems in head and neck cancer patients getting radiation therapy compared to the usual imaging method.

  Recruiting Early Phase 1 Emory University · Atlanta, Georgia · NCT06914999

• Camonsertib added to precise radiation therapy for recurrent head and neck cancer

  This early-phase study tests whether the cancer drug camonsertib, given with targeted SBRT radiation, is safe and tolerable for people with recurrent or unresectable head and neck squamous cell carcinoma.

  Recruiting at 4 sites Phase 1 National Cancer Institute (NCI) · Duarte, California and 3 other locations · NCT07156227

• Cemiplimab with or without CDX-1140 given before surgery for stage III-IV head and neck cancer

  This trial tests whether adding the immune stimulant CDX-1140 to cemiplimab before surgery helps shrink tumors in people with resectable stage III-IV head and neck squamous cell carcinoma.

  Recruiting at 12 sites Phase 2 National Cancer Institute (NCI) · Irvine, California and 11 other locations · NCT06980038

• Combining Ipatasertib with Chemotherapy and Radiation for Head and Neck Cancer

  This study is testing if adding a new drug called ipatasertib to chemotherapy and radiation can help people with advanced head and neck cancer feel better and improve their treatment results.

  Recruiting at 13 sites Phase 1 National Cancer Institute (NCI) · Tampa, Florida and 17 other locations · NCT05172245

• Adding chemotherapy or chemo-immunotherapy to standard salvage surgery for advanced head and neck cancer

  This trial tests whether giving chemotherapy alone or chemotherapy plus the immunotherapy cemiplimab before salvage surgery helps people with PD-L1–positive recurrent or persistent head and neck squamous cell carcinoma.

  Recruiting at 114 sites Phase 2 National Cancer Institute (NCI) · Tucson, Arizona and 114 other locations · NCT07195734

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.